Sponsored sessions
Please find below all detailed program items of the sponsored sessions during ANR2023
Sponsored breakfast meeting I: Y-Mabs
Sponsored by Y-mAbs
Date: Tuesday 16 May 2023
Time: 08:00 – 08:45 hrs.
Please join us as experts discuss current challenges and strategies of approaching high-risk neuroblastoma and discuss the evolving science related to the specifics of the disease. This session will review the importance of approaching a patient holistically, as well as assessing and addressing specific needs for patients with high-risk neuroblastoma, such as disease in the bone and bone marrow.
Sponsored breakfast meeting II: Understanding global disparities in access to neuroblastoma immunotherapy
Sponsored by Partner Therapeutics
Date: Wednesday 17 May 2023
Time: 08:00 – 08:45 hrs.
Moderator:
Jaume Mora, MD, PhD
Scientific Director
Pediatric Cancer Center Barcelona
Hospital Sant Joan de Déu. Barcelona, Spain
Outlines
- Treatment landscape evolution: pre and post anti-GD2 immunotherapy
- Variations in immunotherapy treatment options: Anti-GD2 antibodies/world map
- Highlights/differences in immunotherapy treatment guidelines
- Response rates/OS data for anti-GD2 combination therapies.
- What scientific questions need to be answered? Future studies?
- Closing remarks
Plenary session 6: Genetic drivers of resistance and relapse
Sponsored by Neuroblastoma UK
Date: Thursday 18 May 2023
Time: 09:00 – 10:00 hrs.
Parallel sessions 15: How patient advocates can help improve the survival of children with neuroblastoma
Sponsored by Villa Joep, Research at Solving kids’ Cancer and Neuroblastoma UK
Date: Thursday18 May 2023
Time: 11:15 – 12:05 hrs.
Sponsored lunch meeting I: Managing bone and bone marrow involvement in neuroblastoma with anti-GD2 therapy
This activity is supported by an independent educational grant from Y-mAbs Therapeutics, Inc.
Date: Thursday 18 May 2023
Time: 12:20 – 13:50 hrs.
Sponsored lunchmeeting II: High- risk neuroblastoma in 2035
Sponsored by Solving Kids Care Cancer
Date: Thursday 18 May 2023
Time: 12:20 – 13:50 hrs.
Chair: Prof Andy Pearson
Presenters: Leona Knox, Prof Rochelle Bagatelle
Panel: Leona Knox, Nick Bird, Advocate (US), Prof Rochelle Bagatelle, Dr Steve DuBois, Prof Maja Beck, Dr Lucas Moreno
Therapy for children with high-risk neuroblastoma has changed dramatically and outcomes have greatly improved in the past decades, but much remains to be done to increase survival rates and decrease late effects of treatment. To move the field forward and improve outcomes for all children with high-risk neuroblastoma, we must develop a vision for neuroblastoma therapy that extends beyond what is right around the corner, and consider the paradigm shifts that will be required to turn our broad vision into reality. Please join us for an interactive session that will be of interest to laboratory-based scientists, neuroblastoma trialists, clinical care providers and parent advocates as we take a birds’ eye view and challenge ourselves to think expansively about how neuroblastoma will be treated in 2035 … and beyond.
